The translational limitations of these receptors have clinical implications as htr1a has been extensively studied as a target for mood disorders, adora2a is suggested as a therapeutic target for neurodegenerative disorders, blood–brain barrier integrity, immunosuppression, cancer, and angiogenesis (Borea et al., 2018; Pasquini et al., 2021), and adgrf1 is proposed as a novel therapeutic for cancer and inflammation (Abdulkareem et al., 2021; Huang et al., 2020; Park et al., 2019). This evidence concerns the gene ADGRF1 and cancer.